Celltrion is preparing to make a filing in the second half for the regulatory approval in the EU of a subcutaneous version of its infliximab biosimilar Remsima, the first biosimilar with a changed formulation, in an effort to diversify its portfolio and boost the product's market competitiveness.
Celltrion Inc. is gearing up to file a marketing authorization with the European Medicines Agency for Remsima SC, a subcutaneous (SC) version of its autoimmune disease therapeutic antibody infliximab, a biosimilar version of Johnson & Johnson's Remicade, following the completion of a Phase III clinical trial.
Celltrion said it is set to complete the clinical analysis for the trial soon and to submit the approval application...
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
